【査読付き英文論文】

*1. Hamamoto R, Nakamura Y: Dysregulation of protein methyltransferases in human cancer: an emerging target class for anticancer therapy. Cancer Science, 107, 377-384 (2016)

*2. Piao L, Nakakido M, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R: Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins. Oncotarget, 7, 22846-22856 (2016)

*3. Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park J-H, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R: WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget, 7, 42527-42538 (2016)

*4. Kunizaki M, Sawai T, Takeshita H, Tominaga T, Hidaka S, To K, Miyazaki T, Hamamoto R, Nanashima A, Nagayasu T: Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer. Anticancer Research, 36, 4171-4175 (2016)

*5. Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Park J-H, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y: The prognostic impact of jumonji domain containing 2B in patients with resected lung adenocarcinoma. Anticancer Research, 36, 4841-4846 (2016)

*6. Yoshioka Y, Suzuki T, Matsuo Y, Nakakido M, Tsurita G, Simone C, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R†: SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget, 7, 75023-75037 (2016)

*7. Deng Y, Wang H, Hamamoto R, Duan S, Pirooznia M, Bai Y: Functional Genomics, Genetics, and Bioinformatics 2016. BioMed Research International, Article ID 2625831 (2016)